Tomorrow, John Lechleiter takes over from
Sidney Taurel as CEO of Eli Lilly and Co.
A chemist who came up through Lillyâ??s labs, marketing and finally, as president and chief operating officer, Lechleiter faces major pressure.
Lilly stock has trended sideways for more than three years as investors impatiently look for news that the company can replace its top-selling Zyprexa and other major drugs as their patents expire.
With state government as a major employer as well as lots of small- and medium-sized businesses across a number of sectors, Indianapolis enjoys economic stability many cities can only dream of. But Lilly is still critical to the regionâ??s prosperity.
How do you feel about Lillyâ??s future under Lechleiter?
A chemist who came up through Lillyâ??s labs, marketing and finally, as president and chief operating officer, Lechleiter faces major pressure.
Lilly stock has trended sideways for more than three years as investors impatiently look for news that the company can replace its top-selling Zyprexa and other major drugs as their patents expire.
With state government as a major employer as well as lots of small- and medium-sized businesses across a number of sectors, Indianapolis enjoys economic stability many cities can only dream of. But Lilly is still critical to the regionâ??s prosperity.
How do you feel about Lillyâ??s future under Lechleiter?
Back to Top
IBJ Conversations
0 Comments
Add Comment